Material Agreement Form 8 K

Item 1.01 Entry into a Material Definitive Agreement.

On November 8, 2024, Adicet Therapeutics, Inc. (the "Subsidiary"), a Delaware corporation and wholly-owned subsidiary of Adicet Bio, Inc. (the "Guarantor", and together with the Subsidiary, the "Company"), and Pacific Western Bank ("PacWest") entered into a Eighth Amendment (the "Amendment") to that certain Loan and Security Agreement, dated April 28, 2020, by and among the Subsidiary and PacWest (the "Agreement"). Pursuant to the Agreement, PacWest will provide one or more term loans, as well as non-formula ancillary services.

Pursuant to the Amendment, the Company and PacWest agreed to amend certain provisions of the Agreement that relate to Adicet (Shanghai) Biotechnology Co., Ltd. ("Adicet Shanghai"). The provisions include (i) the removal of the equity interests of Adicet Shanghai held by the Company from the general requirement to pledge all assets owned by the Company as collateral, and (ii) a permitted investment dollar threshold of $500,000 for cash that the Company can transfer to Adicet Shanghai without additional Bank approval.

The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the agreement, which is attached to this report as Exhibit 10.1 and incorporated by reference in this Item 1.01.